Prepared by Dr. David Miller, FRM, Head of Quantitative Research | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-8D484E43-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns is raymond james a good investment company a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 77.85x, -9.4% revenue expansion, and an RSI of 68 suggesting a neutral-bullish phase. We define critical support at $5382 and resistance at $6578.
Rating: Overweight | Target Price: $8372 | Next Earnings: Jun 17
Download Full PDF Report
Price action carved a Ascending Triangle, confirmed by a 1.45x volume spike on May 19, 2026. The support at $5382 was tested.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $6877 would be bullish.
MACD printed a Bullish Crossover as the 50-day SMA turned positive 9 days ago.
Relative to Healthcare peers, is raymond james a good investment company sits at the 92th percentile in valuation, offering a potential value opportunity.
With a market cap of $19.94B, is raymond james a good investment company operates in Healthcare. P/E of 77.85x is backed by -9.4% growth.
Options skew is toward put at the 5860.4 strike, positioning for a directional move.
Short float at 9.6% is below the sector average, reducing squeeze risk. Institutional ownership is 84%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $5980 | $5681 |
| Market Cap | $19.94B | $19.94B |
| P/E Ratio | 77.85x | 66.2x |
| EPS (TTM) | $76.81 | $69.13 |
| Dividend Yield | 2.88% | 2% |
| Revenue Growth | -9.4% | -5.6% |
| Target Price | $8372 | - |
| Beta | 0.67 | 1.00 |